April 15, 2019
Allele Biotechnology and SCM Lifescience Sign a Joint Research and Development Agreement to Develop iPSC-based Diabetes Treatment
San Diego-based Allele Biotechnology and Pharmaceuticals, Inc.,officially announced a joint research and development agreement withSouth Korea’s SCM Lifescience Co., Ltd., for the development of diabetestherapies using pancreatic beta cells derived from induced pluripotentstem cells (iPSCs).